The Fanconi Anemia Group E Gene, FANCE, Maps to Chromosome 6p  by Waisfisz, Quinten et al.
Am. J. Hum. Genet. 64:1400–1405, 1999
1400
The Fanconi Anemia Group E Gene, FANCE, Maps to Chromosome 6p
Quinten Waisfisz,1∗ Kathrin Saar,3,4∗ Neil V. Morgan,5∗ Cigdem Altay,7 Peter A. Leegwater,2
Johan P. de Winter,1 Kenshi Komatsu,8 Gareth R. Evans,6 Rolf-Dieter Wegner,3 Andre´ Reis,3,4
Hans Joenje,1 Fre´ Arwert,1 Christopher G. Mathew,5 Jan C. Pronk,1 and Martin Digweed3
1Departments of Human Genetics, Free University, and 2Clinical Chemistry, Academic Hospital of the Free University, Amsterdam;
3Institute of Human Genetics, Charite´–Campus Virchow-Klinikum, Humboldt University, and 4Microsatellite Centre, Max Delbru¨ck Center for
Molecular Medicine, Berlin; 5Division of Medical and Molecular Genetics, GKT School of Medicine, Guy’s Hospital, London, and
6Department of Medical Genetics, St. Mary’s Hospital, Manchester, United Kingdom; 7Department of Paediatrics, Haematology Unit,
Hacettepe University, Ankara, Turkey; and 8Department of Radiation Biology, Research Institute for Radiation Biology and Medicine,
Hiroshima University, Hiroshima
Summary
Fanconi anemia (FA) is a genetically heterogeneous au-
tosomal recessive disease with bone marrow failure and
predisposition to cancer as major features, often accom-
panied by developmental anomalies. The cells of patients
with FA are hypersensitive to DNA cross-linking agents
in terms of cell survival and chromosomal breakage. Of
the eight complementation groups (FA-A to FA-H) dis-
tinguished thus far by cell fusion studies, the genes for
three—FANCA, FANCC, and FANCG—have been iden-
tified, and the FANCD gene has been localized to chro-
mosome 3p22-26. We report here the use of homozy-
gosity mapping and genetic linkage analysis to map a
fifth distinct genetic locus for FA. DNA from three fam-
ilies was assigned to group FA-E by cell fusion and com-
plementation analysis and was then used to localize the
FANCE gene to chromosome 6p21-22 in an 18.2-cM
region flanked by markers D6S422 and D6S1610. This
study shows that data from even a small number of
families can be successfully used to map a gene for a
genetically heterogeneous disorder.
Introduction
The autosomal recessive disorder Fanconi anemia (FA;
MIM 227650) is clinically characterized by progressive
bone marrow failure, sometimes associated with skeletal
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abnormalities and an increased cancer risk. The spon-
taneous chromosomal breakage seen in patient cells, and
exacerbated by exposure to DNA cross-linking agents,
suggests that defective DNA repair is a major conse-
quence of the gene mutation. However, the unusual sen-
sitivity of FA cells to oxygen and their cell-cycle anom-
alies have led to other hypotheses on the basic defect
underlying FA (see Auerbach et al. 1998 for a current
review of FA).
Genetically heterogeneous disorders present a chal-
lenge to gene localization by linkage analysis, unless pa-
tients can be classified into discrete genetic groups on
the basis of clinical, biochemical, or cellular phenotype.
Patients with FA present with a variable clinical picture,
but the hypersensitivity of their cells to DNA cross-link-
ers has allowed their assignment to eight complemen-
tation groups after cell fusion and analysis of cross-linker
sensitivity in cell hybrids (Joenje et al. 1997). Locali-
zation of the major FA gene, FANCA, was facilitated by
linkage analysis in families assigned to the FA-A com-
plementation group (Pronk et al. 1995), and the FANCG
gene was similarly localized in (partially) assigned FA
families (Saar et al. 1998). The cloning of the FANCC
gene (Strathdee et al. 1992a) allowed its localization to
chromosome 9q by use of FISH (Strathdee et al. 1992b),
and the FANCD gene has been localized to chromosome
3p by use of microcell-mediated chromosome transfer
(Whitney et al. 1995). The chromosomal localization of
FA genes has provided starting points for molecular clon-
ing of, or has allowed verification of, complementing
cDNAs for FANCA (The Fanconi Anaemia/Breast Can-
cer Consortium 1996; Lo Ten Foe et al. 1996) and
FANCG (de Winter et al. 1998) and is an important
goal for the remaining FA complementation groups.
We assigned families to FA complementation group E
by use of cell fusion and measurement of the sensitivity
of the hybrids to Mitomycin C, a DNA cross-linking
agent (Sigma). DNA from three assigned families was
then analyzed by use of microsatellite markers for link-
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Figure 1 Homozygosity mapping of microsatellite markers
spaced at 11-cM intervals in FA family 1. Each box represents a mi-
crosatellite marker located on the 22 autosomes; 274 markers were
analyzed. Solid boxes indicate markers that were informative and ho-
mozygous in the affected child EUFA130 only; hatched boxes indicate
markers that were homozygous in EUFA130 but not fully informative;
open boxes indicate markers that were heterozygous in EUFA130; and
missing boxes indicate further markers of the MDC-Ge´ne´thon panel
that were not analyzed.
age to FANCE. By use of homozygosity mapping in two
families and standard linkage analysis in the third, we
identified a chromosomal region on chromosome 6p as
the location of the FANCE gene.
Subjects and Methods
Subjects
Families with FA were recruited as part of the Euro-
pean Concerted Action on Fanconi Anemia Research
(EUFAR). DNA samples from three families were used
for the linkage analyses presented here (pedigrees are
shown in fig. 2). Family 1 is of Turkish origin, and the
parents are first cousins. Their affected son, patient
EUFA130, was the first FA-E patient identified (Joenje
et al. 1995), and his lymphoblastoid cell line is the ref-
erence for the FA-E group (MIM 600901). Family 2 is
from Bangladesh and is not consanguineous. Material
from an affected aborted fetus was available for analysis.
Family 3 (patient EUFA622) is of Turkish origin and the
parents are second cousins. All patients were given their
diagnosis on the basis of their chromosomal hypersen-
sitivity to DNA cross-linking agents. Lymphoblastoid B
cell lines were established from the blood of all family
members by Epstein-Barr virus transformation. Clinical
features of these patients have been documented (patient
EUFA130, Wegner et al. 1996; patients EUFA409 and
EUFA410, Evans et al. 1994; and patient EUFA622, A.
Koc, M. Alikasifoglu, H. Joenje, and C. Altay, unpub-
lished data).
Cell Fusion and Complementation of Cross-Linker
Sensitivity
After the first patient with FA-E was identified (patient
EUFA130; Joenje et al. 1995), the patient’s cell line was
genetically marked to allow its use as a universal fusion
donor. Genetic marking was with G418 resistance
and hypoxanthine-guanine phosphoribosyl transferase
(HPRT) deficiency, as described earlier for the cell lines
of groups FA-B to FA-D (Joenje et al. 1995). The genetic
markers allowed hybrids obtained with any unmarked
cell line to be selected by use of culturing in the presence
of medium containing hypoxanthine, aminopterin, and
thymidine in combination with the drug G418, as de-
scribed elsewhere (Joenje et al. 1995). Cell fusion, se-
lection of hybrids, and assessment of complementation
were all performed as described elsewhere (Joenje et al.
1997). To exclude inadvertent mix-ups of cell lines dur-
ing cell culturing, we authenticated hybrids and trans-
fected cell lines by comparing the alleles we found by
use of VNTR minisatellite markers with those present
in the original cell lines.
To assess whether chromosome loss was a possible
cause of lack of complementation in noncomplemented
hybrids, we checked ploidy of the selected cell popula-
tions by counting chromosomes in 20 randomly selected
metaphases. No evidence for any significant chromo-
some loss was obtained, since chromosome numbers
were in the range of 72-96 per cell (Joenje et al. 1997).
Genotyping
DNA was isolated from lymphoblastoid cell lines by
use of standard techniques and analyzed by use of mi-
crosatellite markers from the MDC-Ge´ne´thon mapping
panel, with an average spacing of 11 cM, or from the
Weber 6B Screening Set, with an average spacing of 10.9
cM. Markers were amplified by PCR by use of fluores-
cently labeled primers and analyzed on the Pharmacia
ALF or ABI 310 sequencers. Length was determined by
use of an internal standard and Genescan 1.2 and Gen-
otyper software (Applied Biosystems). The two initial
analyses used data from (1) all members of family 1 or
(2) patients EUFA130 and EUFA622 together with the
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Figure 2 Most likely haplotypes for microsatellite markers on chromosome 6p. Family 1, with complementation group E reference patient
EUFA130, is consanguineous; the parents are first cousins. Family 2 was assigned in this report to complementation group E. Family 3 is
consanguineous and was assigned in this report to complementation group E; the parents are second cousins. Symbols for affected individuals
are solid.
affected children from family 2, patients EUFA409 and
EUFA410. Data from the entire families were then an-
alyzed for candidate FANCE regions.
Linkage Analysis
We performed two-point LOD score calculation by
use of version 5.1 of LINKAGE software, assuming a
fully penetrant autosomal recessive mode of inheritance,
a gene frequency of 0.0001, and uniform allele frequen-
cies. Multipoint LOD scores based on the experimentally
proven genetic homogeneity were calculated with
GENEHUNTER software, version 1.3, again with an
assumption of uniform allele frequencies. Recombina-
tion frequencies between markers were taken from Dib
et al. (1996) and the Cooperative Human Linkage
Centre.
Results
Cell Fusion and Assignment to FA Complementation
Group E
Lymphoblastoid cell lines from patients EUFA410 and
EUFA622 were fused with reference cell lines repre-
senting groups FA-A to FA-E. As summarized in table
1, findings showed that all fusion hybrids were comple-
mented for MMC sensitivity except the hybrids obtained
with the reference group E cell line EUFA130NT-L.
These results were taken as evidence that the two pa-
tients belonged to complementation group E.
Candidate FANCE Regions
As shown in figure 1, microsatellite mapping in family
1 excluded 70% of the genome for FANCE and iden-
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Table 1
Complementation Analysis of Cells from Patients
EUFA410 and EUFA622
TYPE OF CELL
CELL LINE
EUFA410-L EUFA622-L
Unfused cells 2.1 .5 2.1 1.1
Hybrids after fusion with
reference cell line:
HSC72OT (A) 92.5  9.6 68.3  12.6
HSC230NT (B) 100  0 68.3  10.4
HSC536NT (C) 57.5  9.6 43.3  7.6
HSC62NT (D) 55  21.2 38.5  7.6
EUFA130NT (E) 2.5  .7 4.5  1.3
NOTE.—Results are IC50 values of the two cell lines and
hybrids, given as Mitomycin C concentrationsmean SE
in nmol/l, obtained after fusion with the indicated refer-
ence cell lines. Complementation group is indicated in
parentheses.
Figure 3 Multipoint analysis of chromosome 6 markers in FA-
E families.
tified several candidate regions, particularly on chro-
mosomes 1, 6, 7, 12, and 19. The second genome scan,
using data from the two children of consanguineous par-
ents (patients EUFA130 and EUFA622) and data from
the two affected children (patients EUFA409 and
EUFA410) in family 2, excluded a further 12% of the
genome and left only the candidate regions on chro-
mosomes 6p and 19q, of 44 and 23 cM, respectively.
Examination of additional microsatellite markers on
chromosome 19 for data from all family members in all
three FA-E families gave a maximum LOD score of
at for marker D19S226 in families 1Z  1.20 v  0max
and 3; however, family 2 was not linked at that marker
and showed negative LOD scores for all values of v
between 0 and 0.4. Thus, the candidate region on chro-
mosome 19 could be excluded.
Fine Mapping of Chromosome 6p
Figure 2 shows the most likely haplotypes for 15
markers on chromosome 6p in the three FA-E families.
In family 1, patient EUFA130 is homozygous for a large
region of 73.5 cM from D6S422 to D6S434. As ex-
pected, the homozygous region is smaller in patient
EUFA622 in consanguineous family 3, at 36.5 cM be-
tween D6S422 and D6S452. Family 3 defines D6S422
as the most distal flanking marker. The two affected
children and the affected aborted fetus in family 2 have
identical haplotypes from D6S309 to D6S1548, and the
unaffected child has inherited only the maternal hap-
lotype here. The recombination in the paternal chro-
mosome of the aborted fetus between D6S1548 and
D6S1610 makes the latter marker the current proximal
flanking marker. Thus, on the basis of the genetic dis-
tances between individual markers in this region (Dib et
al. 1996), the current critical region spans 18.2 cM. The
statistical significance of this result is illustrated in figure
3, which shows a plot of the multipoint LOD scores
along chromosome 6p, with for D6S1691.Z  4.55max
Discussion
The extreme degree of genetic heterogeneity in FA re-
quires that families be assigned to a genetic comple-
mentation group before linkage analysis is possible. This
results in some complementation groups with relatively
few families, and localization of the causative genes for
these is possible only by exploiting highly informative
techniques such as homozygosity mapping. In this ap-
proach, a region of many centimorgans surrounding a
disease gene is expected to be homozygous by descent
in the affected child of consanguineous parents (Lander
and Botstein 1987). Such chromosomal regions can be
rapidly ascertained by analysis of highly polymorphic
microsatellite markers. This method has previously been
used in the mapping of the FANCA and FANCG genes
(Pronk et al. 1995; Saar et al. 1998).
The initial analysis of data from family 1 was powerful
enough to exclude 70% of the genome. A second anal-
ysis using just the affected children in families 1, 2, and
3 led to exclusion of 82% of the genome and identified
two major candidate regions on chromosomes 6 and 19.
Analysis of further markers in all family members ex-
cluded the region on chromosome 19, whereas the region
on chromosome 6p was substantiated by a multipoint
Zmax of 4.55 for D6S1691. This clearly reflects the power
of multipoint linkage analysis, because the maximum
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Figure 4 Map of microsatellite markers on chromosome 6p and
the FANCE gene. Genetic distances are indicated in centimorgans
(cM). Physical locations of makers are taken from the consensus map
of chromosome 6p (Genome Data Base).
two-point LOD score obtained was atZ  2.68max
for marker D6S461.v  0
As shown in figure 4, FANCE is located on chro-
mosome 6p between markers D6S422 and D6S1610 in
cytogenetic band 6p21.2-22.3. This is an extremely
gene-rich region, containing clusters of histone genes,
the complement C4 genes, and the human leukocyte an-
tigen (HLA) class I genes of the major histocompatibility
complex. This has significant therapeutic consequences
for patients with FA assigned to this complementation
group. The life-threatening bone marrow insufficiency
in patients with FA is treated, when possible, by bone
marrow transplantation from an HLA-matched unaf-
fected sibling. The location of FANCE among the HLA
class I genes, reported in the present article, suggests that
patients with FA-E are unlikely to have unaffected sib-
lings who are HLA compatible. For these patients, only
unrelated HLA-matched individuals or HLA-matched
parents will be suitable donors.
There are several genes in the critical region that could
be compatible with the cellular and clinical phenotype
of FA and thus represent candidate genes. These include
genes involved in cell-cycle regulation and apoptosis
(CCND3, CDKN1, and BAK), an oxygen-regulated
protein (ORP150), and the lymphokine LTA (tumor ne-
crosis factor–b). Mutation analysis of these candidates
in FA-E patients is in progress.
The localization of a further FA gene to a discrete
chromosomal region reconfirms the genetic heteroge-
neity of this disease. At this stage, both the proportion
of FA cases caused by a mutation of the FANCE gene
and their geographic distribution are unclear. However,
the FANCE gene’s chromosomal mapping provides a
basis for its identification and will have consequences
for the diagnosis and treatment of FA.
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